Omega-3處方藥市場規模、份額和趨勢分析報告：按分銷渠道（醫院、在線藥房）、應用（高甘油三酯血症）、藥物（Vascepa、Lovaza）、地區、細分市場預測2022-2030

Omega-3 處方藥市場增長和趨勢

Grand View Research, Inc. 的一份新報告預測，到 2030 年，全球 omega-3 處方藥市場規模將達到 25.2 億美元，在預測期內的複合年增長率為 8.27%。該行業的增長是由於心血管疾病（CVD）病例數量的增加和飲食的變化。現在已知血液甘油三酯水平升高與心血管疾病風險增加有關。根據歐洲心髒病學會 2021 年的數據，每年有 1790 萬人死於 CVD，使其成為全球主要死因。此外，隨著產品在藥品中的應用潛力不斷擴大，預計行業參與者推出基於 omega-3 的藥物將促進其增長。

例如，2020 年，美國 FDA 批准了美國 Amarin 生產的 omega-3 藥物 VASCEPA 的新心血管適應症和擴大標籤。增加甘油三酯使動脈變窄，增加心肌梗塞和中風的風險。胰腺炎是胰腺的炎症，也可能由極高的值引起。糖尿病和肥胖症導致甘油三酯水平升高，這是一個常見問題。平均 25% 的美國成年人血液中的酒精含量處於臨界水平。 Omega-3 脂肪酸藥物僅適用於 500 mg/dl 或更高水平的甘油三酯，這是美國 FDA 批准的。在 COVID-19 大流行期間，Omega-3 處方藥出現了重大的市場變動。

這是由於其在 CVD 患者管理中的重要作用。例如，2021 年 8 月，Woodward Pharma Services LLC宣布已從GlaxoSmithKline手中收購 LOVAZA。該公司還旨在教育消費者和醫療保健提供者，以促進該產品的更高采用率。此外，針對降低甘油三酯進行了多項研發研究，對 17 項提高甘油三酯水平的有組織、隨機臨床試驗結果的綜合分析表明，處方 omega-3 脂肪酸藥物降低了 20%~30%建議減少。預計這將產生較高的產品需求。

Omega-3 處方藥市場報告亮點

由於 Vacepa 已獲 FDA 批准用於降低 CVD 風險的患者，因此 Vacepa 藥物部分將在 2021 年佔銷售額的最大份額。

通過應用，預計高甘油三酯血症部分將在預測期內實現最快的增長率。

這種增長是由於甘油三酯水平升高的患者使用 omega-3 處方藥的增加。

2021 年，北美在全球行業中占主導地位，因為 CVD 是該地區的首要死因和目標疾病的高流行率。

主要參與者正專注於利用現有藥物開發先進的新型劑型，以滿足不斷增長的需求並提供有效的治療選擇。

內容

第 1 章 Omega-3 處方藥市場：研究方法和範圍

• 調查方法
• 調查假設
• 信息採購
  • 購買的數據庫
  • GVR 內部數據庫
  • 輔助信息
  • 初步調查
  • 初步調查的內容
• 信息或數據分析
  • 數據分析模型
• 市場製定和驗證
• 型號詳情
  • 商品流向分析
    • 方法 1：商品流通方法
  • 量價分析（模型 2）
    • 方法 2：體積分析
    • 收入建模
• 輔助信息列表
• 主要信息列表

第 2 章 Omega-3 處方藥市場：執行摘要

• 市場概覽

第 3 章 Omega-3 處方藥市場：行業展望

• 市場系列展望
  • 母公司市場展望
• 繪製滲透率和增長前景
• 市場動態
  • 市場驅動因素分析
    • 心血管疾病、肥胖症和高甘油三酯血症的患病率不斷上升
    • 開髮用於治療相關疾病的新型治療劑
    • 對免疫補充劑的擔憂日益增加
    • 久坐不動的生活方式、傾向於在家工作、缺乏鍛煉
  • 市場約束分析
    • 與 omega-3 處方藥相關的高成本
• 波特五力分析
• 按因素（政法、經濟、技術）進行 SWOT 分析
• 監管框架
• 用戶視角分析

第 4 章 Omega-3 處方藥市場：競爭格局

• 主要市場參與者的近期趨勢和影響分析
  • Ansoff Matrix
• Major deals &strategic alliances analysis
  • 合資企業
  • 許可和合作夥伴關係
  • 技術合作
• 公司/競爭對手分類
• 供應商情況
  • 主要分銷商和渠道合作夥伴列表
  • 主要客戶
• 上市公司
  • 公司市場分析
• 私人公司
  • 主要初創企業列表
  • 本地網絡地圖

第 5 章 Omega-3 處方藥市場：醫藥業務分析

• 定義和範圍
• 類型市場份額分析，2021 年和 2030 年
• 2018-2030 年全球 Omega-3 處方藥市場，按藥物分類
• 2018-2030 年市場規模和預測、趨勢分析
  • 維塞帕
  • 洛瓦薩
  • 其他

第 6 章 Omega-3 處方藥市場：應用業務分析

• 定義和範圍
• 2021 年和 2030 年應用市場份額分析
• 2018-2030 年全球 Omega-3 處方藥市場（按應用）
• 2018-2030 年市場規模和預測、趨勢分析
  • 高甘油三酯血症
  • 其他

第 7 章 Omega-3 處方藥市場：分銷渠道業務分析

• 定義和範圍
• 2021 年和 2030 年應用市場份額分析
• 2018-2030 年全球 Omega-3 處方藥市場，按分銷渠道
• 2018-2030 年市場規模和預測、趨勢分析
  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 8 章 Omega-3 處方藥市場：區域業務分析

• 定義和範圍
• 2021 年和 2030 年區域市場份額分析
• 區域市場信息中心
• 區域市場概況
• 按因素（政治和法律、經濟和技術）進行 SWOT 分析
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 多邊環境協定
• 2021-2030 年市場規模、預測、趨勢分析
• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 意大利
  • 西班牙
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳大利亞
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 多邊環境協定
  • 南非
  • 沙特阿拉伯
  • 阿拉伯聯合酋長國

第 9 章 Omega-3 處方藥市場：公司概況

• 公司簡介
  • Abbott
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Amarin Pharmaceuticals Ireland Limited
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • GSK plc（GlaxoSmithKline Plc）
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Natrapharm, Inc.（Patriot Pharmaceutical Corp.）
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Viatris Inc.
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Grupo Ferrer Internacional, SA
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Camber Pharmaceuticals, Inc.
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Dr. Reddy's Laboratories Ltd.
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Zydus Group
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措
  • Hikma Pharmaceuticals PLC
    • 公司概況
    • 財務表現
    • 產品基準
    • 戰略舉措

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 8.27% over the forecast period, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

• The vascepa drug segment accounted for the largest revenue share in 2021 as vascepa is approved by the FDA for use in patients for reducing the risk of CVD

• By application, the hypertriglyceridemia segment is expected to register the fastest growth rate over the forecast period

• The growth can be attributed to the increasing use of omega 3 prescription medications for patients with elevated triglyceride levels

• North America dominated the global industry in 2021 owing to the high prevalence of target diseases, with CVD being the leading cause of death in the region

• Key players are focusing on developing advanced and novel dosage forms from existing drugs to meet the rising demand and provide efficient treatment options

Table of Contents

Chapter 1 Omega 3 Prescription Drugs Market: Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates and forecast timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.6.2 Volume price analysis (model 2)
    • 1.6.2.1 Approach 2: Volume price analysis
    • 1.6.2.2 Revenue modeling
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources

Chapter 2 Omega 3 Prescription Drugs Market: Executive Summary

• 2.1 Market summary

Chapter 3 Omega 3 Prescription Drugs Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Increasing prevalence of cardiovascular diseases, obesity and hypertriglyceridemia
    • 3.3.1.2 Development of novel drugs for treatment of related disease condition
    • 3.3.1.3 Rising concerns related to immunity supplements
    • 3.3.1.4 Sedentary lifestyles, the trend toward working from home, and a lack of physical activity
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost associated with omega 3 prescription drugs
• 3.4 Porter's Five Forces Analysis
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Regulatory Framework
• 3.7 User Perspective Analysis

Chapter 4 Omega 3 Prescription Drugs Market: Competitive Landscape

• 4.1 Recent developments & impact analysis, by key market participants
  • 4.1.1 Ansoff Matrix
• 4.2 Major deals & strategic alliances analysis
  • 4.2.1 Joint Ventures
  • 4.2.2 Licensing and Partnerships
  • 4.2.3 Technological Collaborations
• 4.3 Company/Competition Categorization
• 4.4 Vendor Landscape
  • 4.4.1 List Of Key Distributors and Channel Partners
  • 4.4.2 Key Customers
• 4.5 Public Companies
  • 4.5.1 Company Market Position Analysis
• 4.6 Private Companies
  • 4.6.1 List Of Key Emerging Companies
  • 4.6.2 Regional Network Map

Chapter 5 Omega 3 Prescription Drugs Market: Drug Business Analysis

• 5.1 Definition and Scope
• 5.2 Type Market Share Analysis, 2021 & 2030
• 5.3 Global Omega 3 Prescription Drugs Market, By Drugs, 2018 to 2030
• 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1 Vascepa
    • 5.4.1.1 Vascepa Market 2018 - 2030 (USD Million)
  • 5.4.2 Lovaza
    • 5.4.2.1 Lovaza Market, 2018 - 2030 (USD Million)
  • 5.4.3 Others
    • 5.4.2.3 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Omega 3 Prescription Drugs Market: Application Business Analysis

• 6.1 Definition and Scope
• 6.2 Application Market Share Analysis, 2021 & 2030
• 6.3 Global Omega 3 Prescription Drugs Market, By Application, 2018 to 2030
• 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1 Hypertriglyceridemia
    • 6.4.1.1 Hypertriglyceridemia Market 2018 - 2030 (USD Million)
  • 6.4.2 Others
    • 6.4.2.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 Omega 3 Prescription Drugs Market: Distribution Channel Business Analysis

• 7.1 Definition and Scope
• 7.2 Application Market Share Analysis, 2021 & 2030
• 7.3 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 to 2030
• 7.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 7.4.1 Hospital Pharmacy
    • 7.4.1.1 Hospital Pharmacy Market 2018 - 2030 (USD Million)
  • 7.4.2 Retail Pharmacy
    • 7.4.2.1 Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 7.4.2 Online Pharmacy
    • 7.4.2.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8 Omega 3 Prescription Drugs Market: Regional Business Analysis

• 8.1 Definition & Scope
• 8.2 Regional Market Share Analysis, 2021 & 2030
• 8.3 Regional Market Dashboard
• 8.4 Regional Market Snapshot
• 8.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 8.5.1 North America
  • 8.5.2 Europe
  • 8.5.3 Asia Pacific
  • 8.5.4 Latin America
  • 8.5.5 MEA
• 8.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 8.7 North America
  • 8.7.1 North America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.2 U.S.
    • 8.7.2.1 U.S. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.7.3 Canada
    • 8.7.3.1 Canada Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.8 Europe
  • 8.8.1 Europe Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.2 U.K.
    • 8.8.2.1 U.K. Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.3 Germany
    • 8.8.3.1 Germany Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.4 France
    • 8.8.4.1 France Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.5 Italy
    • 8.8.5.1 Italy Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.8.6 Spain
    • 8.8.6.1 Spain Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.9 Asia Pacific
  • 8.9.1 Asia-Pacific Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.2 Japan
    • 8.9.2.1 Japan Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.3 China
    • 8.9.3.1 China Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.4 India
    • 8.9.4.1 India Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.5 Australia
    • 8.9.5.1 Australia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.9.6 South Korea
    • 8.9.6.1 South Korea Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.10 Latin America
  • 8.10.1 Latin America Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.2 Brazil
    • 8.10.2.1 Brazil Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.3 Mexico
    • 8.10.3.1 Mexico Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.10.4 Argentina
    • 8.10.4.1 Argentina Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
• 8.11 MEA
  • 8.11.1 MEA Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.2 South Africa
    • 8.11.2.1 South Africa Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.3 Saudi Arabia
    • 8.11.3.1 Saudi Arabia Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)
  • 8.11.4 UAE
    • 8.11.4.1 UAE Omega 3 Prescription Drugs Market, 2018 - 2030 (USD Million)

Chapter 9 Omega 3 Prescription Drugs Market: Company Profiling

• 9.1 Company Profiles
  • 9.1.1. Abbott
    • 9.1.1.1 Company overview
    • 9.1.1.2 Financial performance
    • 9.1.1.3 Product benchmarking
    • 9.1.1.4 Strategic Initiatives
  • 9.1.2. Amarin Pharmaceuticals Ireland Limited
    • 9.1.2.1 Company overview
    • 9.1.2.2 Financial performance
    • 9.1.2.3 Product benchmarking
    • 9.1.2.4 Strategic Initiatives
  • 9.1.3. GSK plc (GlaxoSmithKline Plc)
    • 9.1.3.1 Company overview
    • 9.1.3.2 Financial performance
    • 9.1.3.3 Product benchmarking
    • 9.1.3.4 Strategic Initiatives
  • 9.1.4. Natrapharm, Inc. (Patriot Pharmaceutical Corp.)
    • 9.1.4.1 Company overview
    • 9.1.4.2 Financial performance
    • 9.1.4.3 Product benchmarking
    • 9.1.4.4 Strategic Initiatives
  • 9.1.5. Viatris Inc.
    • 9.1.5.1 Company overview
    • 9.1.5.2 Financial performance
    • 9.1.5.3 Product benchmarking
    • 9.1.5.4 Strategic Initiatives
  • 9.1.6. Grupo Ferrer Internacional, S.A.
    • 9.1.6.1 Company overview
    • 9.1.6.2 Financial performance
    • 9.1.6.3 Product benchmarking
    • 9.1.6.4 Strategic Initiatives
  • 9.1.7. Camber Pharmaceuticals, Inc.
    • 9.1.7.1 Company overview
    • 9.1.7.2 Financial performance
    • 9.1.7.3 Product benchmarking
    • 9.1.7.4 Strategic Initiatives
  • 9.1.8 Dr. Reddy's Laboratories Ltd.
    • 9.1.8.1 Company overview
    • 9.1.8.2 Financial performance
    • 9.1.8.3 Product benchmarking
    • 9.1.8.4 Strategic Initiatives
  • 9.1.9 Zydus Group
    • 9.1.9.1 Company overview
    • 9.1.9.2 Financial performance
    • 9.1.9.3 Product benchmarking
    • 9.1.9.4 Strategic Initiatives
  • 9.1.10 Hikma Pharmaceuticals PLC
    • 9.1.10.1 Company overview
    • 9.1.10.2 Financial performance
    • 9.1.10.3 Product benchmarking
    • 9.1.10.4 Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Omega 3 Prescription Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 6 Global Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 7 Global Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 10 North America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 11 North America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 13 U.S. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 14 U.S. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 16 Canada Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 17 Canada Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Europe Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 20 Europe Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 21 Europe Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 U.K. Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 23 U.K. Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 24 U.K. Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Germany Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 26 Germany Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 27 Germany America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 France Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 29 France Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 30 France Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Spain Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 32 Spain Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 33 Spain Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Italy Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 35 Italy Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 36 Italy Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Asia Pacific Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 38 Asia Pacific Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 China Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 42 China Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 43 China Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Japan Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 45 Japan Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 46 Japan Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 47 India Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 48 India Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 49 India Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 South Korea Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 51 South Korea Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 52 South Korea Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Australia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 54 Australia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 55 Australia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 Latin America Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 57 Latin America Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 58 Latin America Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 59 Latin America Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Brazil Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 61 Brazil Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 62 Brazil Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Mexico Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 64 Mexico Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 65 Mexico Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Argentina Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 67 Argentina Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 68 Argentina Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 69 MEA Omega 3 Prescription Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 70 MEA Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 71 MEA Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 72 MEA Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 South Africa Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 74 South Africa Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 75 South Africa Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Saudi Arabia Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 UAE Omega 3 Prescription Drugs Market, By Application, 2018 - 2030 (USD Million)
• Table 80 UAE Omega 3 Prescription Drugs Market, By Drug, 2018 - 2030 (USD Million)
• Table 81 UAE Omega 3 Prescription Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Omega 3 Prescription Drugs Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Omega 3 Prescription Drugs Market: Drug Movement Analysis
• Fig. 16 Vascepa market, 2018 - 2030 (USD Million)
• Fig. 17 Lovaza market, 2018 - 2030 (USD Million)
• Fig. 18 Others market, 2018 - 2030 (USD Million)
• Fig. 19 Omega 3 Prescription Drugs Market: Application Movement Analysis
• Fig. 20 Hypertriglyceridemia market, 2018 - 2030 (USD Million)
• Fig. 21 Others market, 2018 - 2030 (USD Million)
• Fig. 22 Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
• Fig. 23 Hospital Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 24 Retail Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 25 Online Pharmacy market, 2018 - 2030 (USD Million)
• Fig. 26 Regional Marketplace: Key Takeaways
• Fig. 27 Regional Outlook, 2018 & 2030
• Fig. 28 Regional Market Dashboard
• Fig. 29 Regional Market Place: Key Takeaways
• Fig. 30 North America, SWOT Analysis
• Fig. 31 Europe, SWOT Analysis
• Fig. 32 Asia Pacific, SWOT Analysis
• Fig. 33 Latin America, SWOT Analysis
• Fig. 34 MEA, SWOT Analysis
• Fig. 35 North America
• Fig. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 37 U.S.
• Fig. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 39 Canada
• Fig. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 41 Europe
• Fig. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 43 U.K.
• Fig. 44 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 45 Germany
• Fig. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 47 France
• Fig. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 49 Italy
• Fig. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 Spain
• Fig. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Asia Pacific
• Fig. 54 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Japan
• Fig. 56 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 China
• Fig. 58 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 India
• Fig. 60 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 Australia
• Fig. 62 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 South Korea
• Fig. 64 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Latin America
• Fig. 66 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Brazil
• Fig. 68 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Mexico
• Fig. 70 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Argentina
• Fig. 72 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 MEA
• Fig. 74 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 South Africa
• Fig. 76 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia
• Fig. 78 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 UAE
• Fig. 80 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Strategy Mapping